Asenapine Sublingual Tablets Articles
Merck & Co’s integrated pipeline has over 20 drugs and vaccines in late-stage development
2 March 2010
Emerging oral atypical antipsychotics will garner only limited uptake in schizophrenia market
25 February 2010
Merck & Co rises 2.3% as it beats 4th quarter 2009 sales forecast, boosted by Schering-Plough
17 February 2010
Schering-Plough gets US approval for Saphris
17 August 2009
FDA Committee backs Schering-Plough’s Saphris
3 August 2009
S-P responds to FDA's questions on Saphris NDA
2 March 2009
FDA requests more existing data on S-P's Saphris before approval
19 January 2009
S-P claims superior pipeline to competitors; new drugs could make $7B in next 4 years
8 December 2008
S-P's Saphris effective in schizophrenia relapse
1 December 2008
Showing 1-13 of 13 articles
- 1
- Ono Pharma buys Japanese rights to two cancer drugs in $340 million deal with Onyx
- GlaxoSmithKline sells Croatian research center to Galapagos, names new CFO and enters supply deal with Lonza; EMEA update on Avandia and Pandemrix
- Wyeth/Pfizer accused of using ghostwritten articles to overstate benefits of HRT
- China’s liver cancer drug market forecast to nearly triple to $144 million in 2014
- International sales rep quality survey views BRIC markets
